Trial Profile

A phase 2a, open-label study of visilizumab in patients with moderate-to-severe inflammatory, nonstricturing, nonpenetrating forms of Crohn's disease.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Visilizumab (Primary)
Indications Crohn's disease
Focus Therapeutic Use
Sponsors PDL BioPharma

Most Recent Events

27 Jul 2011 Status changed from discontinued to completed as reported by ISRCTN: Current Controlled Trials record.
28 May 2011 Additional trial locations (Germany, Netherlands) identified as reported by ISRCTN: Current Controlled Trials record.
28 May 2011 New source identified and integrated (ISRCTN: Current Controlled Trials record).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com